Second-Generation Pharmacological Chaperones: Beyond Inhibitors

My Lan Tran (1) , Yves Génisson (1) , Stéphanie Ballereau (1) , Cécile Baudoin-Dehoux (1)

1 SPCMIB - Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique

Protein misfolding induced by missense mutations is the source of hundreds of conformational diseases. The cell quality control may eliminate nascent misfolded proteins, such as enzymes, and a pathological loss-of-function may result from their early degradation. Since the proof of concept in the 2000s, the bioinspired pharmacological chaperone therapy became a relevant low-molecular-weight compound strategy against conformational diseases. The first-generation pharmacological chaperones were competitive inhibitors of mutant enzymes. Counterintuitively, in binding to the active site, these inhibitors stabilize the proper folding of the mutated protein and partially rescue its cellular function. The main limitation of the first-generation pharmacological chaperones lies in the balance between enzyme activity enhancement and inhibition. Recent research efforts were directed towards the development of promising second-generation pharmacological chaperones. These non-inhibitory ligands, targeting previously unknown binding pockets, limit the risk of adverse enzymatic inhibition. Their pharmacophore identification is however challenging and likely requires a massive screening-based approach. This review focuses on second-generation chaperones designed to restore the cellular activity of misfolded enzymes. It intends to highlight, for a selected set of rare inherited metabolic disorders, the strategies implemented to identify and develop these pharmacologically relevant small organic molecules as potential drug candidates.

Mots clés: pharmacological chaperones; lysosomal storage disease; allosteric ligand; conformational disease; non-inhibitory chaperones

Domaines: Chimie

My Lan Tran, Yves Génisson, Stéphanie Ballereau, Cécile Baudoin-Dehoux. Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules, 2020, 25 (14), pp.3145. ⟨10.3390/molecules25143145⟩. ⟨hal-02899344⟩